ArticleJournal of medicinal chemistry2026
Design of New Potent, Selective, and Long-Acting NOP Receptor Agonists through Multiple Sequential d-Amino Acid Substitutions of [Arg14 Lys15]N/OFQ(1-15)-NH2.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
The nociceptin/orphanin FQ (N/OFQ) receptor (NOP) ligands are drug candidates for different diseases, but peptide ligands are often limited by rapid enzymatic degradation and short in vivo duration of action. Here, we applied a multiple D-amino acid substitution strategy to the peptide template [Arg14 Lys15]N/OFQ(1-15)-NH2 to improve metabolic stability while preserving receptor activity. Progressive substitutions revealed marked positional tolerance within the C-terminal address domain and identified [d-Lys13,15d-Arg14]N/OFQ(1-15)-NH2 (compound 1c) as the most promising compound. This led to the Cha1-containing analogue 3a, which retained full agonist efficacy and high selectivity at the NOP receptor in vitro and ex vivo. In vivo, compound 3a induced a long-lasting loss of the righting reflex in mice, closely overlapping the pharmacological profile of the potent and long-acting agonist UFP-112. These findings define the stereochemical tolerance of the NOP receptor toward multiple d-amino acid substitutions within the N/OFQ peptide and demonstrate that this information can be exploited as a rational design strategy to generate NOP receptor agonists with prolonged in vivo activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.